Table 1 Summary of studies included in the review
Author, Year | Country | Population/ Setting | Comparator strategiesa | Data | Baseline parameters | Resultsa | ||
|---|---|---|---|---|---|---|---|---|
HBsAg prevalence | Cascade of Care | |||||||
Screening uptake | Linkage to care & Adherence to treatment | |||||||
Eckman, 2011 [23] | USA | General population (primary care) | • Screen & treat (4 regimens) • No screening | CEA; Hypothetical cohort | 2% | ns | 100% adherence | $29,230/QALY (2008) |
Nayagam, 2016 [22] | The Gambia | General population (community) | • Screen & treat • Status quo | CEA; Screening data | 8.8% | 68.9% | 81.3% linkage, 80.9% adherence | $540/DALY ($645/LY, $511/ QALY) (2013) |
Wong, 2011 [27] | Canada | Migrants (primary care) | • Screen & treat • Screen, treat & vaccinate • Status quo (no screening) | CEA; Hypothetical cohort | 4.81% | 100% | 90% of all eligible will receive treatment | C$69,209/QALY (2008) |
Rossi, 2013 [25] | Canada | Newly arrived Migrants | • Universal vac • Screen & vac • Screen & treat • Screen, treat & vac • No intervention | CEA; Hypothetical cohort | 6.5% | 70% | 60% linkage, 75% eligible will have treatment | C$40,880/QALY (2011) |
Hutton, 2007 [24] | USA | Asian & pacific islander adults | • Universal vac • Screen & treat • Screen, treat & ring vac • Screen, treat & vac • No intervention | CEA; Hypothetical cohort | 10% | 70% | 100% will accept medical treatment | $36,000/QALY (2006) |
Jazwa, 2015 [30] | USA | Overseas testing of refugees | • Vaccination only • Screen, vac & treat | CBA; Hypothetical cohort | 6.8% | 100% | 60% linkage, 90% adherence | $90 M net benefit after 5 yearsb (2012) |
Veldhuijzen, 2010 [28] | Holland | Migrants | • Screen & treat • Status quo | CEA; Hypothetical cohort | 3.35% | 35% | 58% linkage, 75% adherence | €8966/QALY |
Rein, 2011 [26] | USA | Asian Migrant population (primary care & outreach) | • Comparison of 4 screening methods | CEA; Screening data | 5.6–6.6% | n/a | n/a | $40- $280 per complete screen. $609–$4657 per positive case detected (2008) |
Ruggeri, 2011 [29] | Italy | High risk groups | • Screen & treat • No screening | CEA; Hypothetical cohort | 7% | 100% | 100% adherence | €18,225/QALY |